Bio­gen en­lists un­der-the-radar AAV en­gi­neers as it pumps gene ther­a­pies in­to the pipeline

Bio­gen, fac­ing a thin pipeline be­yond their con­tro­ver­sial lead Alzheimer’s can­di­date, has been load­ing up on gene ther­a­py col­lab­o­ra­tions, hop­ing to find their next break­through from the emerg­ing field.

To aid in that search, they have now en­list­ed a new com­pa­ny that just launched to take on one of the biggest tech­ni­cal chal­lenges in gene ther­a­py: Build­ing vec­tors that can safe­ly de­liv­er healthy genes to the right tis­sues and cell types and on­ly the right tis­sues and cell types.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER